person · Reporting owner
Parschauer Karah Herdman
Disclosed activity across 5 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anebulo Pharmaceuticals, Inc.ANEB · Entity 9617 | Director | April 21, 2022 | October 03, 2022 |
| Arcturus Therapeutics Holdings Inc.ARCT · Entity 5523 | Director | June 18, 2021 | June 22, 2021 |
| Evolus, Inc.EOLS · Entity 5341 | Director | February 17, 2026 | February 20, 2026 |
| Tenaya Therapeutics, Inc.TNYA · Entity 6506 | Director | May 28, 2026 | May 29, 2026 |
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | EVP and Chief Legal Officer | August 03, 2026 | August 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anebulo Pharmaceuticals, Inc.
Report date April 21, 2022 · Filed October 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2027-02-28 | Direct | 30,425 |
Reported balance
After 2022-04-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-04-21 · Grant · Acquired 30,425 · Balance 30,425 F1: 25% of the option vests on March 1, 2023. Thereafter, 1/48 of the option vests on a monthly basis over 36 months until the option becomes fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the option vests on March 1, 2023. Thereafter, 1/48 of the option vests on a monthly basis over 36 months until the option becomes fully vested.
Arcturus Therapeutics Holdings Inc.
Report date June 18, 2021 · Filed June 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.09 · Expires 2031-06-18 | Direct | 15,000 |
Reported balance
After 2021-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-18 · Grant · Acquired 15,000 · Balance 15,000 F1: Shares underlying the option vest monthly over a one year period from the date of grant. This grant represents the annual grant to members of the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares underlying the option vest monthly over a one year period from the date of grant. This grant represents the annual grant to members of the Board of Directors.
Evolus, Inc.
Report date February 17, 2026 · Filed February 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 77,742 |
Reported balance
After 2026-02-17 transaction · row 1
1 source rowRow 1 · 2026-02-17 · Grant · Acquired 45,559 · Balance 77,742 F1: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of February 17, 2026, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of February 17, 2026, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer.
Tenaya Therapeutics, Inc.
Report date May 28, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2036-05-27 | Direct | 120,000 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 120,000 · Balance 120,000 F1: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.
Ultragenyx Pharmaceutical Inc.
Report date August 03, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 92,562 |
Reported balance
After 2026-08-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-03 · Sale · Disposed 1,900 · Balance 92,562 F1: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2021 Filed Sep 9, 2021 22:22 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionCommon Stock | 7,336 | $54.50 | $399,812.00 |
DisclosureSEC source: 0001209191-21-055362 · doc4.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 22:33 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $35.09 | $0.00 |
DisclosureSEC source: 0001193805-21-000929 · e620749_4-parschauer.xml · derivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-18 F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This grant represents the annual grant to members of the Board of Directors. Read SEC document |
| June 10, 2021 Filed Jun 12, 2021 01:08 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 1,329 | $100.00 | $132,900.00 |
DisclosureSEC source: 0001209191-21-040108 · doc4.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,668 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| May 06, 2021 Filed May 10, 2021 22:13 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 313 | $113.67 | $35,578.71 |
DisclosureSEC source: 0001209191-21-031388 · doc4.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,997 F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes 83 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2021. F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:47 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $142.47 | $0.00 |
DisclosureSEC source: 0001209191-21-017559 · doc4.xml · derivative · entry 4 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2031-03-01 F6 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:47 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 3,970 | $138.17 | $548,534.90 |
DisclosureSEC source: 0001209191-21-017559 · doc4.xml · nonDerivative · entry 3 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,227 F3 · kind: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.16 to $138.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:47 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 4,636 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017559 · doc4.xml · nonDerivative · entry 2 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,197 F2 · shares: Represents 1,530 shares of common stock and 3,106 RSUs into which previously granted performance stock units were converted on March 1, 2021 upon certification of the performance metric. The RSUs will fully vest on March 1, 2022. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:47 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017559 · doc4.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,561 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:12 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantCommon Stock | 19,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-21-000035 · wf-form4_161290871645474.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,313 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of February 5, 2021, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. Read SEC document |
| October 30, 2020 Filed Nov 2, 2020 22:05 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,903 | $0.00 Strike: $54.50 | $0.00 |
DisclosureSEC source: 0001209191-20-056428 · doc4.xml · derivative · entry 3 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 9,903 shares Expires 2026-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested with respect to 1/4th of the shares on June 20, 2017 (the first anniversary of the grant date of the option or the "Option Anniversary Date") and 1/48th of the shares initially subject to the option continued to vest on each month as measured from the Option Anniversary Date such that the option fully vested on the fourth anniversary of the grant date. Read SEC document |
| October 30, 2020 Filed Nov 2, 2020 22:05 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 9,903 | $100.12 | $991,488.36 |
DisclosureSEC source: 0001209191-20-056428 · doc4.xml · nonDerivative · entry 2 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,061 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F4 · balance_after: Includes 93 shares acquired under the Company's 2014 Employee Stock Purchase Plan on October 31, 2020. Read SEC document |
| October 30, 2020 Filed Nov 2, 2020 22:05 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionCommon Stock | 9,903 | $54.50 | $539,713.50 |
DisclosureSEC source: 0001209191-20-056428 · doc4.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| October 28, 2020 Filed Oct 30, 2020 21:28 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 97 | $0.00 Strike: $54.50 | $0.00 |
DisclosureSEC source: 0001209191-20-056344 · doc4.xml · derivative · entry 3 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,903 Underlying: Common Stock · 97 shares Expires 2026-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested with respect to 1/4th of the shares on June 20, 2017 (the first anniversary of the grant date of the option or the "Option Anniversary Date") and 1/48th of the shares initially subject to the option continued to vest on each month as measured from the Option Anniversary Date such that the option fully vested on the fourth anniversary of the grant date. Read SEC document |
| October 28, 2020 Filed Oct 30, 2020 21:28 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 97 | $100.00 | $9,700.00 |
DisclosureSEC source: 0001209191-20-056344 · doc4.xml · nonDerivative · entry 2 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,968 F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| October 28, 2020 Filed Oct 30, 2020 21:28 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionCommon Stock | 97 | $54.50 | $5,286.50 |
DisclosureSEC source: 0001209191-20-056344 · doc4.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 23:21 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 325 | $88.00 | $28,600.00 |
DisclosureSEC source: 0001209191-20-055179 · doc4.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,968 F1 · shares: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| October 08, 2020 Filed Oct 13, 2020 21:53 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $54.50 | $0.00 |
DisclosureSEC source: 0001209191-20-054710 · doc4.xml · derivative · entry 3 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 10,000 shares Expires 2026-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested with respect to 1/4th of the shares on June 20, 2017 (the first anniversary of the grant date of the option or the "Option Anniversary Date") and 1/48th of the shares initially subject to the option continued to vest on each month as measured from the Option Anniversary Date such that the option fully vested on the fourth anniversary of the grant date. Read SEC document |
| October 08, 2020 Filed Oct 13, 2020 21:53 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 10,000 | $95.00 | $950,000.00 |
DisclosureSEC source: 0001209191-20-054710 · doc4.xml · nonDerivative · entry 2 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,293 F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| October 08, 2020 Filed Oct 13, 2020 21:53 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionCommon Stock | 10,000 | $54.50 | $545,000.00 |
DisclosureSEC source: 0001209191-20-054710 · doc4.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 18:57 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $48.43 | $0.00 |
DisclosureSEC source: 0001209191-20-054110 · doc4.xml · derivative · entry 3 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 10,000 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested with respect to 1/4th of the shares on March 1, 2019 (the first anniversary of the grant date of the option or the "Option Anniversary Date") and 1/48th of the shares initially subject to the option continued to vest on each month as measured from the Option Anniversary Date such that the option will fully vest on the fourth anniversary of the grant date. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 18:57 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 10,000 | $90.00 | $900,000.00 |
DisclosureSEC source: 0001209191-20-054110 · doc4.xml · nonDerivative · entry 2 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,293 F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 18:57 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionCommon Stock | 10,000 | $48.43 | $484,300.00 |
DisclosureSEC source: 0001209191-20-054110 · doc4.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 23, 2020 Filed Sep 24, 2020 20:47 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $48.43 | $0.00 |
DisclosureSEC source: 0001209191-20-051900 · doc4.xml · derivative · entry 3 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 10,000 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested with respect to 1/4th of the shares on March 1, 2019 (the first anniversary of the grant date of the option or the "Option Anniversary Date") and 1/48th of the shares initially subject to the option continued to vest on each month as measured from the Option Anniversary Date such that the option will fully vest on the fourth anniversary of the grant date. Read SEC document |
| September 23, 2020 Filed Sep 24, 2020 20:47 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 10,000 | $85.00 | $850,000.00 |
DisclosureSEC source: 0001209191-20-051900 · doc4.xml · nonDerivative · entry 2 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,293 F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| September 23, 2020 Filed Sep 24, 2020 20:47 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionCommon Stock | 10,000 | $48.43 | $484,300.00 |
DisclosureSEC source: 0001209191-20-051900 · doc4.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 18:12 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $54.50 | $0.00 |
DisclosureSEC source: 0001209191-20-047456 · doc4.xml · derivative · entry 4 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 10,000 shares Expires 2026-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4th of the shares vested one year from June 20, 2016 and then 1/48th of the option vested monthly thereafter. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 18:12 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 2,370 | $88.39 | $209,484.30 |
DisclosureSEC source: 0001209191-20-047456 · doc4.xml · nonDerivative · entry 3 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,293 F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 18:12 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 10,000 | $88.44 | $884,400.00 |
DisclosureSEC source: 0001209191-20-047456 · doc4.xml · nonDerivative · entry 2 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,663 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.29 to $88.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 18:12 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionCommon Stock | 10,000 | $54.50 | $545,000.00 |
DisclosureSEC source: 0001209191-20-047456 · doc4.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,663 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2020 Filed Jun 25, 2020 00:02 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $40.70 | $0.00 |
DisclosureSEC source: 0001193805-20-000746 · e619725_4-parschauer.xml · derivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-21 F1 · derivative.exercise_date: Shares underlying the options vest monthly over a one year period from the date of grant. Read SEC document |
| June 20, 2020 Filed Jun 22, 2020 17:46 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 649 | $78.22 | $50,764.78 |
DisclosureSEC source: 0001209191-20-038110 · doc4.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,663 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| May 18, 2020 Filed May 19, 2020 23:12 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 2,722 | $74.72 | $203,374.23 |
DisclosureSEC source: 0001209191-20-030707 · doc4.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,312 F1 · balance_after: Includes 130 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2020. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| May 06, 2020 Filed May 9, 2020 00:02 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 248 | $66.26 | $16,432.48 |
DisclosureSEC source: 0001209191-20-028111 · doc4.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,904 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| April 19, 2020 Filed Apr 21, 2020 19:36 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 248 | $58.57 | $14,525.36 |
DisclosureSEC source: 0001209191-20-025191 · doc4.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,152 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 01:00 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $56.08 | $0.00 |
DisclosureSEC source: 0001209191-20-015763 · doc4.xml · derivative · entry 4 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2030-03-01 F5 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 01:00 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 2,118 | $56.08 | $118,777.44 |
DisclosureSEC source: 0001209191-20-015763 · doc4.xml · nonDerivative · entry 3 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,400 F4 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 01:00 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 5,634 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015763 · doc4.xml · nonDerivative · entry 2 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,518 F3 · shares: Represents 1,859 shares of common stock and 3,775 RSUs into which previously granted performance stock units were converted on March 1, 2020 upon certification of the performance metric. The RSUs will fully vest on March 1, 2021. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 01:00 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 7,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015763 · doc4.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,884 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| January 23, 2020 Filed Jan 25, 2020 02:06 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantStock Option (Right to Buy) · Derivative | 23,458 | $0.00 Strike: $10.19 | $0.00 |
DisclosureSEC source: 0001570562-20-000034 · wf-form4_157991796400306.xml · derivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,458 Underlying: Common Stock · 23,458 shares Expires 2030-01-23 F1 · derivative.exercise_date: The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of January 23, 2020, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| October 25, 2019 Filed Oct 30, 2019 00:40 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $10.23 | $0.00 |
DisclosureSEC source: 0000899243-19-026159 · doc4.xml · derivative · entry 2 Parschauer Karah Herdman · CIK 0001677455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-10-24 F2 · derivative.exercise_date: Shares underlying the options vest monthly over a two year period from the date of grant. Read SEC document |
| October 25, 2019 Filed Oct 30, 2019 00:40 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $10.23 | $0.00 |
DisclosureSEC source: 0000899243-19-026159 · doc4.xml · derivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-10-24 F1 · derivative.exercise_date: Shares underlying the options vest monthly over a one year period from the date of grant. Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 23:28 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 1,434 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-053324 · doc4.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,084 F1 · shares: Represents restricted stock units (RSUs) into which previously granted performance stock units were converted on October 14, 2019 upon certification of the applicable performance metric. Half of these RSUs will vest on the first anniversary of the certification date and the other half will vest on the second anniversary of the certification date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 20:31 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantCommon Stock · Derivative | 26,163 | $0.00 Strike: $15.99 | $0.00 |
DisclosureSEC source: 0001570562-19-000114 · wf-form4_156339545939626.xml · derivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,163 Underlying: Common Stock · 26,163 shares Expires 2029-07-15 F1 · derivative.exercise_date: The shares subject to the option will vest over a period of two years, with 1/2 of the shares subject to the option vesting annually on the anniversary of July 15, 2019. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 01:16 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 1,226 | $61.50 | $75,399.00 |
DisclosureSEC source: 0001209191-19-038876 · doc4.xml · nonDerivative · entry 3 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,650 F3 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.78 to $62.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| June 21, 2019 Filed Jun 25, 2019 01:16 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 1,489 | $63.01 | $93,821.89 |
DisclosureSEC source: 0001209191-19-038876 · doc4.xml · nonDerivative · entry 2 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,876 F3 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| June 20, 2019 Filed Jun 25, 2019 01:16 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 649 | $63.48 | $41,198.52 |
DisclosureSEC source: 0001209191-19-038876 · doc4.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,365 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| May 06, 2019 Filed May 7, 2019 23:01 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 1,434 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-028097 · doc4.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,014 F1 · shares: Represents restricted stock units (RSUs) into which previously granted performance stock units were converted on May 6, 2019 upon certification of the applicable performance metric. Half of these RSUs will vest on the first anniversary of the certification date and the other half will vest on the second anniversary of the certification date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| April 29, 2019 Filed Apr 30, 2019 22:32 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 468 | $68.30 | $31,964.40 |
DisclosureSEC source: 0001209191-19-026669 · doc4.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,580 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| April 19, 2019 Filed Apr 23, 2019 22:26 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 248 | $64.43 | $15,978.64 |
DisclosureSEC source: 0001209191-19-025614 · doc4.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,048 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 05, 2019 Filed Apr 17, 2019 21:52 UTC Amendment | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 886 | $65.52 | $58,050.72 |
DisclosureSEC source: 0001209191-19-025104 · doc4a.xml · nonDerivative · entry 2 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,296 F3 · shares: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.